Exclusive Free Webinar


Thursday, May 7, 2020 at 1 p.m. EDT

Important Medication Safety Considerations for COVID-19 Treatment

In the COVID-19 fight, medication safety is essential – especially for vulnerable individuals with several chronic diseases who take multiple medications. It has become imperative as the exploration for using repurposed drugs against COVID-19 is underway. While the proposed repurposed medications may potentially be associated with positive outcomes in the management of COVID-19, there are still risks associated. When not used appropriately, effectively, and safely, medications can lead to serious – even fatal – consequences. This webinar will review relevant safety concerns for repurposed medications that are being prescribed or are under investigation for the treatment of COVID-19.

• Understand the relevant history and progression of COVID-19
• Identify the most important proposed treatment options for COVID-19 and understand their mechanism of action, their metabolic pathways and the risk of drug-drug interactions
• Realize the potential for major side-effects, including prolonged QT interval, that may be caused when used in combination
•Through a clinical trial, recognize how simulations will become a good tool for COVID-19 medication management


Richard O. Schamp, MD, Chief Medical Officer, Tabula Rasa HealthCare

Dr. Schamp has more than 30 years’ experience in geriatric care and leadership of healthcare organizations. He has served on faculty in multiple institutions, training hundreds of primary care physicians, pharmacists, nurse practitioners, and physician assistants. As former CEO of Capstone Performance Systems, he is an industry expert in Medicare risk adjustment and clinical documentation. Dr. Schamp has been certified in healthcare ethics, healthcare quality and as a long-term care medical director. Dr. Schamp earned his Doctor of Medicine degree from the University of Kansas.


Jacques Turgeon, B.Pharm., Ph.D., Chief Scientific Officer, Tabula Rasa HealthCare and Chief Executive Officer, TRHC Scientific Precision Pharmacotherapy Research & Development Institute

Dr. Turgeon obtained his B.Pharm. and Ph.D. from Laval University, Quebec City, Canada. He then completed a fellowship training in clinical pharmacology at Vanderbilt University, Nashville Tennessee, USA. Dr. Turgeon is recognized internationally for his excellence in research and pharmacy education. During his academic career, he has received more than $70 million in research awards, authored more than 151 peer-reviewed articles and mentored nearly 70 students. His research interests focus on studying factors responsible for the intersubject variability in drug response, and he is renowned for his expertise on the cytochrome P450 system and for the role of pharmacogenetics in cardiovascular drug actions.

Dr. Turgeon has held numerous leadership roles. These include serving as Research Director of the Quebec Heart Institute; Dean of the School of Pharmacy and Vice-Rector of Research at the University of Montreal; Director of the University of Montreal Hospital Research Centre; Chief Executive Officer of the University of Montreal University Hospital. More recently he served as the Associate Dean, College of Pharmacy, University of Florida. Dr. Turgeon is Professor Emeritus from University of Montreal, a fellow of the Canadian Academy of Health Sciences and an international fellow of the Académie Nationale de Médecine in France

Jacques Turgeon

Veronique Michaud, B.Pharm., Ph.D., Chief Operating Officer, Tabula Rasa HealthCare Scientific Precision Pharmacotherapy Research & Development Institute

Veronique Michaud, B.Pharm., Ph.D. is the Chief Operating Officer of the Tabula Rasa HealthCare Scientific Precision Pharmacotherapy Research & Development Institute in Orlando. The institute aims at developing advanced clinical decision support systems to optimize medication safety. Dr. Michaud is an adjunct professor, Faculty of pharmacy, Université de Montréal and has directed a pharmacokinetic and bioanalytic core facility at the CRCHUM. Her research investigates the contribution of CYP450 drug-metabolizing enzymes in drug disposition, with a special attention to the role of disease states (focusing on type 2 diabetes), the role of pharmacogenomics and drug-drug interactions while attempting to better understand and predict variation in drug responses. She has earned more than $22 million in research awards, published more than 42 peer-reviewed journal articles and mentored graduate students and PharmD residents. Dr. Michaud completed fellowships at Indiana University and McGill University and earned her Ph.D. and M.Sc. degrees from the Université de Montréal.

Veronique Michaud

Who Should Attend:

Health Plans, Medicare Advantage Plans, PACE, Hospitals, Health Systems, ACOs, Providers, Healthcare/Health Plan Consultants

• Pharmacy
• Clinical Services
• Quality Improvement

• Risk Management
• Medical Directors


Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable health plans to optimize medication safety. TRHC focuses on preventing adverse drug events via simultaneous, multi-drug analyses to improve outcomes, efficacy, and adherence, and reduce total cost of care. Through a suite of innovative solutions, TRHC offers vast opportunities for enhancing patient care and satisfaction for payers, providers, and other healthcare organizations. Clients report a 4:1 ROI.